Sign in Subscribe
Genetic research

Lupus Nephritis Research Uncovers New Therapeutic Options

Strategic Insights

— 2 min read

Researchers at the Ralph H. Johnson Veterans Affairs Medical Center have made significant discoveries regarding lupus nephritis, a chronic kidney disease that can lead to progressive kidney injury. The study, published in Lupus Science and Medicine, demonstrated that serum from patients with active lupus nephritis induces uncoupling of endothelial nitric oxide synthase (eNOS) homodimers, leading to the production of superoxide instead of nitric oxide. This finding suggests that the genetic ablation of the eNOS enzyme worsens the disease. The researchers discovered that treatment with L-sepiapterin (L-Sep) can reverse this uncoupling and modulate gene expression in glomerular endothelial cells, promoting endothelial function and reducing oxidative stress.

Key Takeaways:

  • The study revealed that serum from patients with active lupus nephritis induces uncoupling of eNOS homodimers, leading to superoxide production.
  • Treatment with L-sepiapterin reversed this uncoupling and modulated gene expression in glomerular endothelial cells.
  • L-Sep induced genes involved in promoting endothelial function and enriched for pathways related to NO biosynthesis, fatty acid and lipid biosynthesis, and fatty acid synthesis.
  • The research provides the rationale to target endothelial dysfunction in the treatment of lupus nephritis with L-Sep as a therapeutic option.
  • The study highlights the importance of endothelial cells in modulating the disease and suggests that targeting endothelial dysfunction may be a promising approach to treating lupus nephritis.
  • The researchers demonstrated that the addition of L-Sep induced differential gene expression in glomerular endothelial cells cultured with lupus nephritis flare serum.
  • The study provides evidence that glomerular endothelial cells can mount an active inflammatory response in an lupus nephritis serum environment.

Statistics:

  • The study involved 3 disease states: healthy controls (HCs), patients with lupus nephritis during remission (LN rem), and patients with lupus nephritis during flare (LN flare).
  • The researchers used bulk RNA sequencing to determine differential gene expression in glomerular endothelial cells.
  • The study found that L-Sep treatment induced 35% of the differentially expressed genes in glomerular endothelial cells cultured with LN flare serum.
  • The pathways enriched for by L-Sep included NO biosynthetic and metabolic processes, fatty acid and lipid biosynthesis, neurotransmitter biosynthesis, reactive oxygen biosynthesis, and vascular endothelial growth factor production and regulation of smooth muscle contraction.

Sources:

  • Lupus Science and Medicine (BMJ Publishing Group): "Lupus nephritis serum induces changes in gene expression in human glomerular endothelial cells, which is modulated by L-sepiapterin: implications for redox-mediated endothelial dysfunction" (https://doi.org/10.1136/lupus-2025-001568)
  • Health & Medicine Week: "Studies from Ralph H. Johnson Veterans Affairs Medical Center Reveal New Findings on Lupus Nephritis" (June 27, 2025; p 4418)

Read more